文献速递心脑血管急症消化、代谢与肾脏急症

阿哌沙班治疗癌症相关静脉血栓栓塞症

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
PubMed 文献 · N Engl J Med · 2020-03-29
一句话结论在癌症相关静脉血栓栓塞症患者中,口服阿哌沙班在预防复发性静脉血栓栓塞症方面不劣于皮下注射达肝素,且未增加大出血风险。

这项多国、随机、研究者发起的开放标签、非劣效性试验纳入了连续癌症合并症状性或偶然发现的急性近端深静脉血栓或肺栓塞患者,随机接受口服阿哌沙班(前7天10 mg每日两次,之后5 mg每日两次)或皮下达肝素(第一个月200 IU/kg每日一次,之后150 IU/kg每日一次),治疗6个月。主要疗效终点为试验期间客观确认的复发性静脉血栓栓塞症,阿哌沙班组576例中发生32例(5.6%),达肝素组579例中发生46例(7.9%)(HR 0.63;95%CI 0.37-1.07;非劣效性P<0.001)。主要安全性终点大出血阿哌沙班组22例(3.8%),达肝素组23例(4.0%)(HR 0.82;95%CI 0.40-1.69;P=0.60)。

要点

  • 癌症相关静脉血栓栓塞症患者中,阿哌沙班治疗6个月复发性静脉血栓栓塞症发生率5.6%(32/576),达肝素组7.9%(46/579),HR 0.63(95%CI 0.37-1.07),非劣效性P<0.001。
  • 大出血发生率阿哌沙班组3.8%(22例) vs 达肝素组4.0%(23例),HR 0.82(95%CI 0.40-1.69),P=0.60,无显著差异。
  • 阿哌沙班给药方案:前7天10 mg每日两次口服,之后5 mg每日两次,总疗程6个月。
  • 达肝素给药方案:第一个月200 IU/kg每日一次皮下注射,之后150 IU/kg每日一次,总疗程6个月。
  • 该试验为多国、随机、开放标签、盲法中心终点裁决的非劣效性设计,针对癌症合并急性近端深静脉血栓或肺栓塞患者。

适用人群与场景

  • 连续纳入的癌症患者,合并症状性或偶然发现的急性近端深静脉血栓或肺栓塞。
  • 场景为多国、随机、研究者发起的开放标签非劣效性试验,非急诊或ICU特定场景。

处置流程与药物剂量

  • 阿哌沙班组:口服阿哌沙班10 mg每日两次,前7天;之后5 mg每日两次;治疗6个月。
  • 达肝素组:皮下注射达肝素200 IU/kg每日一次,第一个月;之后150 IU/kg每日一次;治疗6个月。

研究设计与关键结果

  • 研究类型:多国、随机、研究者发起的开放标签、非劣效性试验,盲法中心终点裁决。
  • 样本量:阿哌沙班组576例,达肝素组579例。
  • 主要疗效终点:复发性静脉血栓栓塞症,阿哌沙班组32/576(5.6%) vs 达肝素组46/579(7.9%),HR 0.63(95%CI 0.37-1.07),非劣效性P<0.001。
  • 主要安全性终点:大出血,阿哌沙班组22例(3.8%) vs 达肝素组23例(4.0%),HR 0.82(95%CI 0.40-1.69),P=0.60。

证据类型、等级与局限

  • 证据类型:随机对照试验(非劣效性设计)。
  • 结论:口服阿哌沙班在治疗癌症相关静脉血栓栓塞症方面不劣于皮下达肝素,且未增加大出血风险。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于癌症相关急性近端深静脉血栓或肺栓塞患者,口服阿哌沙班(前7天10 mg每日两次,之后5 mg每日两次,共6个月)可作为皮下达肝素的替代选择,不增加大出血风险。
  • 原文结论支持阿哌沙班在癌症相关静脉血栓栓塞症治疗中不劣于达肝素。

指南或共识出处

  • Caravaggio试验(ClinicalTrials.gov NCT03045406),由Bristol-Myers Squibb-Pfizer Alliance资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However, the benefit of these oral agents is limited by the increased risk of bleeding associated with their use.

METHODS: This was a multinational, randomized, investigator-initiated, open-label, noninferiority trial with blinded central outcome adjudication. We randomly assigned consecutive patients with cancer who had symptomatic or incidental acute proximal deep-vein thrombosis or pulmonary embolism to receive oral apixaban (at a dose of 10 mg twice daily for the first 7 days, followed by 5 mg twice daily) or subcutaneous dalteparin (at a dose of 200 IU per kilogram of body weight once daily for the first month, followed by 150 IU per kilogram once daily). The treatments were administered for 6 months. The primary outcome was objectively confirmed recurrent venous thromboembolism during the trial period. The principal safety outcome was major bleeding.

RESULTS: Recurrent venous thromboembolism occurred in 32 of 576 patients (5.6%) in the apixaban group and in 46 of 579 patients (7.9%) in the dalteparin group (hazard ratio, 0.63; 95% confidence interval [CI], 0.37 to 1.07; P<0.001 for noninferiority). Major bleeding occurred in 22 patients (3.8%) in the apixaban group and in 23 patients (4.0%) in the dalteparin group (hazard ratio, 0.82; 95% CI, 0.40 to 1.69; P = 0.60).

CONCLUSIONS: Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding. (Funded by the Bristol-Myers Squibb-Pfizer Alliance; Caravaggio ClinicalTrials.gov number, NCT03045406.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020. PMID: 32223112. doi:10.1056/NEJMoa1915103

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。